MANNKIND CORP Restructuring Charges
MANNKIND CORP (MNKD) reported Restructuring Charges of $2.04 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2018-02-27
- MANNKIND CORP restructuring charges for the quarter ending 2016-12-31 was $13.00K, a 99.55% decline year-over-year.
- MANNKIND CORP restructuring charges for the quarter ending 2015-12-31 was $2.89M.
- MANNKIND CORP restructuring charges for fiscal 2016 was $2.04M, a 66.31% decline from fiscal 2015.
- MANNKIND CORP restructuring charges for fiscal 2015 was $6.04M, a 217.89% increase from fiscal 2014.
- MANNKIND CORP restructuring charges for fiscal 2014 was $1.90M, a 375.00% increase from fiscal 2013.
- MANNKIND CORP restructuring charges for fiscal 2013 was $400.00K.
| Period end | Restructuring Charges 0 month | Restructuring Charges 1 month | Restructuring Charges 3 month | Restructuring Charges 9 month | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|---|
| 2016-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.04M 10-K · filed 2018-02-27 | ||||
| 2016-09-30 | $2.02M 10-Q · filed 2016-11-09 | |||||
| 2015-12-31 | $2.89M 10-Q · filed 2016-11-09 | $6.04M 10-K · filed 2017-03-16 | $5.90M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $3.20M 10-Q · filed 2015-11-09 | |||||
| 2014-12-31 | $1.90M 10-K · filed 2016-03-15 | |||||
| 2013-12-31 | $400.00K 10-K · filed 2016-03-15 | |||||
| 2011-02-10 | $6.70M 10-K · filed 2014-03-03 | $6.70M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |